JP2019537602A5 - - Google Patents

Download PDF

Info

Publication number
JP2019537602A5
JP2019537602A5 JP2019523810A JP2019523810A JP2019537602A5 JP 2019537602 A5 JP2019537602 A5 JP 2019537602A5 JP 2019523810 A JP2019523810 A JP 2019523810A JP 2019523810 A JP2019523810 A JP 2019523810A JP 2019537602 A5 JP2019537602 A5 JP 2019537602A5
Authority
JP
Japan
Prior art keywords
xanthene
methyl
oxy
alkylene
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019523810A
Other languages
English (en)
Japanese (ja)
Other versions
JP7096817B2 (ja
JP2019537602A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2017/056848 external-priority patent/WO2018083635A2/en
Publication of JP2019537602A publication Critical patent/JP2019537602A/ja
Publication of JP2019537602A5 publication Critical patent/JP2019537602A5/ja
Application granted granted Critical
Publication of JP7096817B2 publication Critical patent/JP7096817B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019523810A 2016-11-04 2017-11-03 三環式複素環式誘導体及びその使用 Active JP7096817B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ72576716 2016-11-04
NZ725767 2016-11-04
PCT/IB2017/056848 WO2018083635A2 (en) 2016-11-04 2017-11-03 Tricyclic heterocyclic derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2019537602A JP2019537602A (ja) 2019-12-26
JP2019537602A5 true JP2019537602A5 (enExample) 2020-12-10
JP7096817B2 JP7096817B2 (ja) 2022-07-06

Family

ID=62075593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523810A Active JP7096817B2 (ja) 2016-11-04 2017-11-03 三環式複素環式誘導体及びその使用

Country Status (6)

Country Link
US (1) US11028064B2 (enExample)
EP (1) EP3535243B1 (enExample)
JP (1) JP7096817B2 (enExample)
CN (1) CN110139852A (enExample)
AU (1) AU2017355603A1 (enExample)
WO (1) WO2018083635A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102240821B1 (ko) * 2017-03-13 2021-04-15 광주과학기술원 P2x1 및 p2x3 수용체 길항제로 사용되는 신규한 5-히드록시 피리딘계 화합물 및 이를 포함하는 약학적 조성물
CN108976164A (zh) * 2018-06-20 2018-12-11 南通常佑药业科技有限公司 手性哌啶胺化合物的制备方法及手性拆分剂的回收套用方法
AU2019474803B2 (en) * 2019-11-19 2024-11-07 Provectus Pharmatech, Inc. Composition and method for treating hematologic cancers
JP2023542041A (ja) * 2020-09-21 2023-10-04 ハチソン メディファルマ リミテッド ヘテロ芳香族化合物及びその使用
CN117682951A (zh) * 2022-04-02 2024-03-12 南京农业大学 一种制备二苯芳基醚酯类衍生物的方法
CN115557890B (zh) * 2022-09-01 2024-06-25 宁波大学 一种多取代吖啶酮烷基衍生物及其制备方法和用途
IT202200024963A1 (it) * 2022-12-05 2024-06-05 Angelini Pharma S P A Composti attivatori dei canali potassio Kv7.2/Kv7.3

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1192651A (en) * 1968-01-09 1970-05-20 Sterling Drug Inc Xanthene Derivatives
BE759292A (fr) 1969-11-27 1971-05-24 Allen & Hanburys Ltd Derives de xanthone, leur preparation et leur emploi
US3859286A (en) * 1970-12-11 1975-01-07 Richardson Merrell Inc Bis-basic ketones of xanthene and xanthen-9-one
DE3789299T2 (de) 1986-12-23 1994-08-04 Warner Lambert Co Verbindungen mit antitumoralen und antibakteriellen Eigenschaften.
JP4387804B2 (ja) 2001-04-06 2009-12-24 アフィニアム・ファーマシューティカルズ・インコーポレイテッド FabI阻害剤
ES2350977T3 (es) 2002-11-05 2011-01-28 Glaxo Group Limited Agentes antibacterianos.
US7589103B2 (en) 2003-06-27 2009-09-15 Janssen Pharmaceutica N.V. Tricyclic-bridged piperidinylidene derivatives as 8-opioid modulators
CA2574768A1 (en) 2004-08-05 2006-02-05 Janssen Pharmaceutica N.V. Tricyclic delta-opioid modulators
JP2008515998A (ja) 2004-10-13 2008-05-15 スミスクライン ビーチャム コーポレーション 化合物
KR101464385B1 (ko) 2006-04-19 2014-11-21 노파르티스 아게 6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법
WO2008016661A2 (en) 2006-08-02 2008-02-07 Xanthus Pharmaceuticals, Inc. Morpholino compounds for treating inflammatory and demyelinating diseases and cancers
WO2008048117A2 (en) 2006-10-17 2008-04-24 Auckland Uniservices Limited Synthesis of 5,6-dimethyl-9-oxo-9h-xanthen-4-yl- acetic acid (dmxaa)
EP2076513A1 (en) * 2006-10-20 2009-07-08 Irm Llc Compositions and methods for modulating c-kit and pdgfr receptors
CN101195609B (zh) 2007-09-28 2011-04-20 武汉远大制药集团有限公司 5,6-二甲基呫吨酮-4-乙酸的制备方法及由此方法制备的衍生物和药物制剂
DE102007047495B4 (de) 2007-10-04 2009-07-16 Contitech Kühner Gmbh & Cie. Kg Wellrohrschlauchleitung sowie Verfahren zu deren Herstellung
WO2009073620A2 (en) 2007-11-30 2009-06-11 Newlink Genetics Ido inhibitors
CN101279967B (zh) 2008-05-29 2010-11-10 武汉远大制药集团有限公司 一种治疗癌症的三甲基呫吨酮-4-乙酸药物组合物及其用途
UY31936A (es) 2008-06-26 2010-01-29 Novartis Ag Método para la preparación del ácido 5,6-dimetil-9-oxo-9h-xanten-4-il-acético (dmxaa)
WO2010045551A1 (en) 2008-10-17 2010-04-22 Concert Pharmaceuticals, Inc. Xanthenone-4-acetic acid derivatives
AU2010295622A1 (en) * 2009-09-16 2012-05-10 Cylene Pharmaceuticals, Inc. Tricyclic compounds and pharmaceutical uses thereof
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
JP5739448B2 (ja) 2009-12-21 2015-06-24 アレイ バイオファーマ、インコーポレイテッド cFMS阻害剤としての置換N−(1H−インダゾール−4−イル)イミダゾ[1,2−a]ピリジン−3−カルボキサミド化合物
TWI414520B (zh) 2010-10-06 2013-11-11 Nat Defense Medical Ct 噻噸酮衍生物
UY33801A (es) 2010-12-13 2013-06-28 Array Biopharma Inc COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III
NO2694640T3 (enExample) 2011-04-15 2018-03-17
CA2862981C (en) 2011-12-15 2020-02-25 Bayer Pharma Aktiengesellschaft Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment cancer
GB2498976A (en) 2012-02-01 2013-08-07 Prosidion Ltd GPR119 agonists useful in the treatment of type II diabetes
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2842937B1 (en) 2012-04-23 2018-01-17 Mitsubishi Tanabe Pharma Corporation Amine compound and use thereof for medical purposes
EP3191098A4 (en) * 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors

Similar Documents

Publication Publication Date Title
JP2022185107A5 (enExample)
JP2007534695A5 (enExample)
JP2017501234A5 (enExample)
JP2018522823A5 (enExample)
CA2491895A1 (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
JP2020521730A5 (enExample)
RU2004132844A (ru) Производные бензамида, полехные в качестве ингибиторов деацетилазы гистонов
JP2017531000A5 (enExample)
JP2013533879A5 (enExample)
JP2012507566A5 (enExample)
JP2020527173A5 (enExample)
JP2002080453A5 (enExample)
RU2017145650A (ru) Ингибиторы тирозинкиназы брутона
RU2006122519A (ru) Лечение злокачественных глиом ингибиторами тфр-бэта
NO20071234L (no) Forbindelser som potensierer glutamatreseptor og anvendelse derav innen medisin
JP2006515858A5 (enExample)
JP2016526576A5 (enExample)
JP2012512886A5 (enExample)
JP2014506599A5 (enExample)
RU2001125893A (ru) Производные 3-фенилпиридина и их применение в качестве антагонистов рецептора NK-1
RU2013138834A (ru) N-[3-(5-амино-3,3а,7,7а-тетрагидро-1н-2,4-диокса-6-аза-инден-7-ил)-фенил]-амиды в качестве ингибиторов васе1 и(или) васе2
JP2007501831A5 (enExample)
TWI794844B (zh) 包含經由鏈接子連接之2或更多芳基或雜芳基的新穎羰基亞肼基二氰化物化合物及其用途
JP2016540803A5 (enExample)
JP2008509955A5 (enExample)